[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371721-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371721-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cell-free-dna-fragmentomics-assay-to-discriminate-the-malignancy-of-breast-nodules-and-evaluate-treatment-response","Cell-free DNA Fragmentomics Assay to Discriminate the Malignancy of Breast Nodules and Evaluate Treatment Response","","Fragmentomics-based cell-free DNA assays are evaluated for distinguishing breast cancer from benign nodules when imaging results are inconclusive and early-stage detection is challenging. In a multi-center study of 613 women, whole-genome sequencing cfFrag profiles identified breast cancer using features including fragment size ratio, fragment size distribution, and copy number variation. The optimal three-feature model achieved strong discrimination at low sequencing depth (3×), with 94.1% specificity at 90% sensitivity, and further improved prediction of neoadjuvant chemotherapy response when integrated with radiological and cfDNA methylation data.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cell-free-dna-fragmentomics-assay-to-discriminate-the-malignancy-of-breast-nodules-and-evaluate-treatment-response/371721/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cell-free-dna-fragmentomics-assay-to-discriminate-the-malignancy-of-breast-nodules-and-evaluate-treatment-response/371721.png","ImageObject",300,407,{"name":42,"@type":43},"Stanford","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are imaging-based methods insufficient for women with breast nodules?","Question",{"text":63,"@type":64},"Imaging screening (e.g., mammography and ultrasonography) has high false positive rates, which can lead to unnecessary biopsies and increased discomfort and healthcare burden.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the cfFrag model distinguish malignant breast nodules?",{"text":68,"@type":64},"The study shows cfDNA fragmentomics profiles, especially features including fragment size ratio, fragment size distribution, and copy number variation, provide more distinguishing ability than other tested fragmentomic metrics.",{"name":70,"@type":61,"acceptedAnswer":71},"How is the model evaluated for treatment response?",{"text":72,"@type":64},"The work demonstrates clinical utility by predicting patient responses to neoadjuvant chemotherapy, with enhanced performance when combining cfFrag with radiological results and cfDNA methylation features.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371721,1790323712,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Genomics, Proteomics & Bioinformatics, 2025, 23(2), qzaf028 [https://doi.org/10.1093/gpbjnl/qzaf028](https://doi.org/10.1093/gpbjnl/qzaf028)  \n[Advance access publication: 4 April 2025](Advance access publication: 4 April 2025)  \nOriginal Research  \nCell-free DNA Fragmentomics Assay to Discriminate the Malignancy of Breast Nodules and Evaluate Treatment Response  \nJiaqi Liu (刘嘉琦) 1,2,3,\\#, Yalun Li (李亚伦) 4,\\#, Wanxiangfu Tang (唐皖湘夫) 5,\\#, Tianyi Qian (钱天一) 6,\\#, Lijun Dai (代丽君) 2,\\#, Ziqi Jia (贾梓淇) 3,\\#, Heng Cao (曹恒) 3, Chenghao Li (李成浩) 2, Yuchen Liu (刘煜琛) 3,7, Yansong Huang (黄岩松) 3,7,  \nJiang Wu (吴疆) 3, Dongxu Ma (马东旭) 3, Guangdong Qiao (乔广东) 4, Hua Bao (包华) 5,  \nShuang Chang (常双) 5, Dongqin Zhu (朱冬琴) 5, Shanshan Yang (杨珊珊) 5, Xuxiaochen Wu (吴徐晓辰) 5, Xue Wu (吴雪) 5, Hengyi Xu (徐恒毅) 1,7, Hongyan Chen (陈洪岩) 1, Yang Shao (邵阳) 5, Xiang Wang (王翔) 3, 􀀃 , Zhihua Liu (刘芝华) 1,􀀃 , Jianzhong Su (苏建忠) 2,􀀃  \n1State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China  \n2 Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China  \n3 Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China  \n4 Department of Breast Surgery, Yantai Yuhuangding Hospital, The Affiliated Hospital of Qingdao University, Yantai 264000, China 5 Nanjing Geneseeq Technology Inc., Nanjing 210061, China  \n6 Department of Breast Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China 7School of Clinical Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China  \n􀀃 Corresponding authors: [sujz@wmu.edu.cn](sujz@wmu.edu.cn) (Su J), [liuzh@cicams.ac.cn](liuzh@cicams.ac.cn) (Liu Z), [xiangw@vip.sina.com](xiangw@vip.sina.com) (Wang X) .  \n\\#Equal contribution.  \nHandling Editor: Xiangdong Fang  \nAbstract  \nThe fragmentomics-based cell-free DNA (cfDNA) assays have recently illustrated prominent abilities to identify various cancers from nonconditional healthy controls, while their accuracy for identifying early-stage cancers from benign lesions with inconclusive imaging results remains uncertain. Especially for breast cancer, current imaging-based screening methods suffer from high false positive rates for women with breast nodules, leading to unnecessary biopsies, which add to discomfort and healthcare burden. Here, we enrolled 613 female participants in this multi-center study and demonstrated that cfDNA fragmentomics (cfFrag) is a robust non-invasive biomarker for breast cancer using wholegenome sequencing. Among the multimodal cfFrag profiles, the fragment size ratio (FSR), fragment size distribution (FSD), and copy number variation (CNV) show more distinguishing ability than Griffin, motif breakpoint (MBP), and neomer. The cfFrag model using the optimal three fragmentomics features discriminated early-stage breast cancer from benign nodules, even at a low sequencing depth (3×) . Notably, it demonstrated a specificity of 94. 1% in asymptomatic healthy women at a 90% sensitivity for breast cancer. Moreover, we comprehensively showcased the clinical utility of the cfFrag model in predicting patient responses to neoadjuvant chemotherapy (NAC) and its enhanced performance when combined with multimodal features, including radiological results [area under the curve (AUC) ¼ 0.93–0.94] and cfDNA methylation features (AUC ¼ 0.96) .  \nKey words: Cell-free DNA fragmentomics; Cell-free DNA methylation; Breast cancer; Whole-genome sequencing; Neoadjuvant chemotherapy.  \nReceived: 8 April 2024; Revised: 19 January 2025; Accepted: 21 January 2025.  \n© The Author(s) 2025. Published by Oxford","cbCainOxibA9ZYk4","https://ap.wps.com/l/cbCainOxibA9ZYk4","pdf",7008848,13,"English","# Abstract\n# Introduction\n## Clinical need for improved breast cancer screening\n## Limitations of imaging and conventional biomarkers\n## Rationale for liquid biopsy and epigenetic approaches","[{\"question\":\"Why are imaging-based methods insufficient for women with breast nodules?\",\"answer\":\"Imaging screening (e.g., mammography and ultrasonography) has high false positive rates, which can lead to unnecessary biopsies and increased discomfort and healthcare burden.\"},{\"question\":\"How does the cfFrag model distinguish malignant breast nodules?\",\"answer\":\"The study shows cfDNA fragmentomics profiles, especially features including fragment size ratio, fragment size distribution, and copy number variation, provide more distinguishing ability than other tested fragmentomic metrics.\"},{\"question\":\"How is the model evaluated for treatment response?\",\"answer\":\"The work demonstrates clinical utility by predicting patient responses to neoadjuvant chemotherapy, with enhanced performance when combining cfFrag with radiological results and cfDNA methylation features.\"}]","Cell-free DNA Fragmentomics Assay to Discriminate the Malignancy of Breast Nodules and Evaluate Treatment Response | PDF",1790192703,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a1e9bca76da34b06d493b839a1cc53ee.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f05188a59c557de662976e7b8b653d24.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4a47b691d9866425057ec911515d01d.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/741859db32fe0da689c67f63df33252f.webp",980,1287]